Moomoo AI 已提取核心信息
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
生物技术公司bluebird bio, Inc. 宣布为其最近获得美国食品药品管理局批准的药物LYFGENIA签署第二份基于结果的协议。该协议将LYFGENIA的覆盖范围扩大到约2亿条生命。LYFGENIA于2023年12月8日获得美国食品药品管理局的批准，旨在治疗有血管闭塞事件史的12岁及以上患者的镰状细胞病。该公司计划在即将于2024年1月9日举行的第42届摩根大通医疗年度会议上提供有关LYFGENIA商业发布的更多最新信息。这些信息是在向美国证券交易委员会提交的8-K表报告中披露的，除非此类文件中特别提及，否则根据《交易法》第18条，该报告不被视为已提交，也未以引用方式纳入根据1933年《证券法》或《交易法》提交的任何文件中。
生物技术公司bluebird bio, Inc. 宣布为其最近获得美国食品药品管理局批准的药物LYFGENIA签署第二份基于结果的协议。该协议将LYFGENIA的覆盖范围扩大到约2亿条生命。LYFGENIA于2023年12月8日获得美国食品药品管理局的批准，旨在治疗有血管闭塞事件史的12岁及以上患者的镰状细胞病。该公司计划在即将于2024年1月9日举行的第42届摩根大通医疗年度会议上提供有关LYFGENIA商业发布的更多最新信息。这些信息是在向美国证券交易委员会提交的8-K表报告中披露的，除非此类文件中特别提及，否则根据《交易法》第18条，该报告不被视为已提交，也未以引用方式纳入根据1933年《证券法》或《交易法》提交的任何文件中。
有用
没用
